Sparking Transformation in Healthcare
egnite is a company with a vision:
to identify and improve outcomes for every cardiovascular patient in the U.S.
Gaps in Care Can Lead to Delays in Treatment
Using Big Data to Solve Big Problems
Advancing the Cardiovascular Health of Our Society
egnite is a digital health company leveraging artificial intelligence-driven algorithms and big data to produce business intelligence for healthcare, elevating the role of data in critical decisions.
FOR HEALTH SYSTEMS
FOR LIFE SCIENCES
egnite Trial Accelerator
Aligned with egnite’s mission to close gaps in structural heart patient care, egnite sponsored a study analyzing over 929,000 de-identified echocardiograms from 35 heart programs to further understand the prevalence of VHD in the U.S.
Brennan JM, Petrescu M, McCarthy P, et al. J Am Coll Cardiol. 2022;79(9_Suppl):1723.
Leading hospitals partner with egnite’s CardioCare platform to reduce variability in care and improve guideline-directed therapy for patients with cardiovascular disease.
egnite, Inc. Unveils Research on Mitral Regurgitation at Transcatheter Cardiovascular Therapeutics Conference 2023
Led by Rahul Sharma MBBS, FRACP, and Colleagues, Findings Presented Today at the TCT Conference. Key Findings Demonstrate Patients with Moderate-to-Severe Mitral Regurgitation are 3 Times Less Likely to be Treated Than Patients with Severe Mitral Regurgitation Despite Similar Untreated Mortality...
Philippe Généreux, MD Presents Novel Research on Aortic Stenosis from egnite, Inc.’s Database at Transcatheter Cardiovascular Therapeutics Conference 2023
Led by Philippe Généreux, MD and Colleagues, Findings Presented Today at the TCT Conference. Key Findings Demonstrate Patients With Aortic Stenosis Have Substantial Untreated Mortality Risk Across All Levels of Aortic Stenosis Severity, but Aortic Valve Replacement Rates Remain Low Even for Patients With Severe Aortic Stenosis...
Using AI and Big Data to Speed Up Cardiovascular Clinical Trials
Clinical trials are necessary to ensure the safety and efficacy of new therapies, but they can be time-consuming, costly and inefficient to enroll, slowing down access to lifesaving treatment options. The future of faster clinical trials is here.